1AI — Algorae Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$18.55m
- AU$14.93m
- AU$0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.12 | ||
| Price to Tang. Book | 5.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 220.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.78% | ||
| Return on Equity | -70.91% | ||
| Operating Margin | -2658.61% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.77 | 0.55 | 0.27 | 0 | 0.04 | n/a | n/a | -44.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.
Directors
- Bernie Tuch CHM
- Daya Uka CFO
- John Cowan FID
- Belinda Di Bartolo COO
- Mark Licciardo SEC
- Andrew Kelly NED
- Carolyn Sue NED
- Robert Willcocks IND (65)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 17th, 2003
- Public Since
- September 1st, 2004
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,686,239,419
- Address
- L 7 330 Collins St, MELBOURNE, 3000
- Web
- https://lctglobal.com/
- Phone
- +61 289990970
- Auditors
- BDO East Coast Partnership
Upcoming Events for 1AI
Similar to 1AI
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
FAQ
What is the Algorae Pharmaceuticals share price?
As of Today at 19:01 UTC, shares in Algorae Pharmaceuticals are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Algorae Pharmaceuticals share price performed this year?
Shares in Algorae Pharmaceuticals last closed at AU$0.01 and the price had moved by +22.22% over the past 365 days. In terms of relative price strength the Algorae Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +16.91% over the past year.
What are the analyst and broker recommendations for Algorae Pharmaceuticals?
There is no consensus recommendation for this security.
What is the Algorae Pharmaceuticals dividend yield?
Algorae Pharmaceuticals does not currently pay a dividend.
Does Algorae Pharmaceuticals pay a dividend?
Algorae Pharmaceuticals does not currently pay a dividend.
When does Algorae Pharmaceuticals next pay dividends?
Algorae Pharmaceuticals does not currently pay a dividend.
How do I buy Algorae Pharmaceuticals shares?
To buy shares in Algorae Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Algorae Pharmaceuticals?
As of the previous close price of AU$0.01, shares in Algorae Pharmaceuticals had a market capitalisation of AU$18.55m.
Where are Algorae Pharmaceuticals shares listed?
Here are the trading details for Algorae Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 1AI
What kind of share is Algorae Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Algorae Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Algorae Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Algorae Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Algorae Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -24.69%.
As of the last closing price of AU$0.01, shares in Algorae Pharmaceuticals were trading -11.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Algorae Pharmaceuticals PE Ratio?
The Algorae Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Algorae Pharmaceuticals?
Algorae Pharmaceuticals' management team is headed by:
- Bernie Tuch - CHM
- Daya Uka - CFO
- John Cowan - FID
- Belinda Di Bartolo - COO
- Mark Licciardo - SEC
- Andrew Kelly - NED
- Carolyn Sue - NED
- Robert Willcocks - IND